Evidence map›Paper›PMID 19709875›Full record

ReviewCurrent opinion in biotechnology2009

Engineering next generation proteases.

Mark Pogson, George Georgiou, Brent L Iverson

Abstract readReview
In one paragraph

Review in Current opinion in biotechnology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Prediction and design of protease enzyme specificity using a structure-aware graph convolutional network.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  3. Article
  4. Review
  5. Article
  6. Substrate Sorting by a Supercharged Nanoreactor.Journal of the American Chemical Society · 2018
    Article
  7. Article
  8. Article
  9. Basis for substrate recognition and distinction by matrix metalloproteinases.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  10. Advances in the directed evolution of proteins.Current opinion in chemical biology · 2014
    Review
  11. Article
  12. Engineering of TEV protease variants by yeast ER sequestration screening (YESS) of combinatorial libraries.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mark PogsonInstitute for Cellular and Molecular Biology, The University of Texas at Austin, 1 University Station A4800, Austin, TX 78712, United States.
George Georgiou
Brent L Iverson

Funding

Protease EngineeringR01GM065551 · NIGMS · UNIVERSITY OF TEXAS AUSTIN · PI IVERSON, BRENT L · 2003 to 2012
$2.5M
NIGMS NIH HHS R01 GM065551
6 · The paper itself

Abstract

The engineering of novel and precise sequence specificity into proteases will provide an important route to the development of exciting new tools for analytical, biotechnological, and therapeutic applications. Significant progress has been made in reprogramming protease specificity, largely because of the development of high-throughput assay technologies allowing the isolation of protease variants from large libraries. For example, using directed evolution as well as other approaches, proteases have been reprogrammed to cleave substrates containing a variety of amino acids in the P1 and P1' positions including a post-translationally modified tyrosine, a specificity not yet identified in any naturally occurring protease. Together, these recent advances represent substantial progress that could soon enable the widespread application of engineered proteases.

Indexed as

Protein Engineeringbeta-GalactosidaseFlow CytometryPeptide HydrolasesProtein Processing, Post-TranslationalSaccharomyces cerevisiaeSubstrate Specificitybeta-GalactosidasePeptide Hydrolases

Identifiers

PMID19709875
PMCPMC2763932

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.